Drug Therapy

    Introduction

 
In this section of the blog I'm going to write about drug therapy of the Alzheimer. There are many of drug for this treatment but I'm going to let you know about two, placebo and IVIg. and the effect that couse both.

          

              

             Article             

 

  Namenda was the first drug approved by the FDA for the treatment of symptoms between the moderate to severe stages of Alzheimer's disease. Apparently, this drug protects nerve cells in the brain of excessive amounts of glutamate, a chemical messenger released in large amounts by cells damaged by Alzheimer's disease. When glutamate binds the cell surface receptor through attachment points, calcium can flow freely into the cell, which may lead to cellular degeneration. Namenda can avoid destructive sequence by setting glutamate activity. For many years, Namenda was available in some European to treat Alzheimer's disease in the moderate to severe stage countries, and has been available in the US since October 2003. Namenda is generally well tolerated, the most common side effects are back pain, constipation, diarrhea, dizziness, drowsiness, headache, pain and weight gain.

Treatment for Anxiety, Depression, and Psychosis

  
  Often, Alzheimer's disease progresses, people experience depression, agitation and psychotic symptoms (paranoid thoughts, delusions or hallucinations). These behaviors can be expressed verbally (screaming, repetitive questions, etc.) or physically (by hoarding, pacing slowly, etc.), and can sometimes lead to aggression, hyperactivity or be quarrelsome. Symptoms may have an underlying medical origin, as a drug interaction or physical pain. If you suspect this behavior, you should consult a doctor.Agitation or psychotic behavior can also be caused by something that has changed in the environment of the person. Often, a change in routine, caregivers, or the physical environment can cause fear, anxiety or fatigue and lead to agitation. The individual may be unable to communicate, I feel frustrated by the limitations that affect you, do not understand what is happening or simply forget how to respond appropriately.

Summary

 The therapy as a lot of stage. When the person gets Alzheimer's disease often they appear of anxiety, despair, depression, courage among other. These symptoms are most common in those people, there are a lot  of medications for those symptoms but they must be set

with psychologist who will work with that person and will work with the acceptation of the disease and its consequences. The desire to continue living is the most important thing that the person need and the  support of his family and friends.

Reference

 Forest Laboratories Ireland Ltd. (2013,Octuber). Retrieved from:

http://pi.actavis.com/data_stream.asp?product_group=1901&p=pi&language=E


Article 2

   Twenty-four people with mild to moderate Alzheimers (MMSE 14-26) participated in the trial. For the first six months, eight participants received placebo and 16 received IVIg at four doses ranging from 0.2 grams IVIg per kilogram of body weight every two weeks to 0.8 grams IVIg per kilogram of body weight given once per month (four people each at the four different doses). After six months, all subjects were given IVIg with the raters blinded to dose. The primary outcome measures were two standard measures of cognition and the clinicians observation of change , respectively the ADAS-cog and the ADCS-CGIC, which were administered at baseline and three-month intervals thereafter.   "While there were relatively small numbers of participants in this study, we were nonetheless able to demonstrate that people with Alzheimers who get uninterrupted treatment with IVIg for nine months have statistically significant and clinically relevant improvements on both cognitive and global clinical measures," [Diamanto Tsakanikas] said. "A large-scale, 18-month, multicenter Phase III clinical trial of IVIg in Alzheimers is now getting underway, sponsored by Baxter and the National Institutes of Health, that will test whether IVIg immunotherapy provides long-term benefits and has a disease-modifying effect. Additional studies may be required.

Summary

  The study takes about 40 person with the disease of the Alzheimer changing form lower to moderate. Eight with placebo and sixteen with IgIV.  In nine month those that us IgIV proved an incredible improvement with the treatment. Dr.Tsakanikas tell that with 18 month with IgIV can modified the level of the Alzheimer.

Reference

THE, A. P. (2005, Jun 21). Stopping alzheimers plaque, two experimental therapies being tested seem to slow the disease by keeping a protein from coating and killing brain cells. Newsday Retrieved from http://search.proquest.com/docview/279863803?accountid=44858